APG-2575 Plus Azacitidine

A Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
24 patients (estimated)
Sponsors
Ascentage Pharma Group Inc.
Tags
Antimetabolites, BCL-2 Inhibitor, Hypomethylating Agents (HMA)
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
1664
NCT Identifier
NCT04964518

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.